Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Fulgent Genetics Undervalued?

TheMotleyFool

0 0

Fulgent Genetics (NASDAQ: FLGT) looks poised to significantly beat its year-end investor estimates. In this Motley Fool Live video recorded on November 15, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer question about whether this means Fulgent is undervalued.

With the vast majority of the company's third-quarter revenue coming from COVID-19 testing rather than its core business and considering the general uncertainty over how COVID-19 will progress, it's understandable that investors would discount the current revenue. However, Fulgent seems to be preparing well for a gradual decline in COVID-testing revenue.

Source Fool.com

Like: 0

FLGT

Share